CN106176693A - One is used for treating angina pectoris Neulized inhalation preparation - Google Patents
One is used for treating angina pectoris Neulized inhalation preparation Download PDFInfo
- Publication number
- CN106176693A CN106176693A CN201610772974.0A CN201610772974A CN106176693A CN 106176693 A CN106176693 A CN 106176693A CN 201610772974 A CN201610772974 A CN 201610772974A CN 106176693 A CN106176693 A CN 106176693A
- Authority
- CN
- China
- Prior art keywords
- neulized inhalation
- nitroglycerin
- preparation
- inhalation preparation
- anginal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is to treat angina pectoris Neulized inhalation preparation about preparation one, and this Neulized inhalation preparation comprises the nitroglycerin as active substance, solvent, stabilizer, and or pharmacologically acceptable carrier.The used administering mode of the present invention is simple to operation, it is prone to patient accept, when client need is saved oneself, medicinal liquid is placed in inhalation in atomising device, get final product fast and effeciently relief of symptoms, rescue for patient or send institute's treatment to provide sufficiently long slack time, thus improving the survival probability after angina pectoris morbidity.
Description
Technical field
The present invention is belonging to field of medicine preparations, relates to a kind of Neulized inhalation preparation, is used for treating the heart particularly to one
The Neulized inhalation preparation of angor.
Background technology
Angina pectoris is a kind of due to coronary insufficiency, cause cardiac muscle drastically, temporary transient ischemia causes with anoxia
With clinical syndrome that ictal chest pain or chest discomfort are main performance.Anginal direct pathogenic factor is blood supply of cardiac muscle
Deficiency, and deficiency myocardial blood supply is mostly derived from coronary heart disease, other kinds of heart disease or hypertension out of control and the heart also can be caused to twist
Bitterly.Anginal Clinical Manifestations is shirtfront paroxysmal, squeezing property pain, can be with other symptoms, and pain is predominantly located at breast
Bone rear portion, can be radiated to pareordia and left upper extremity, work or excited often occur.Anginal very harmful, cardiac muscle stalk
Extremely being belonging to one of common anginal harm performance, due to coronary artery acute occlusion, blood flow interrupts, cause sternness and
Lasting IMN, clinical manifestation is that sudden, strong and lasting retrosternal pain, characteristic electrocardio dynamically spread out
Become and the increasing of sero-enzyme；Angina pectoris is also easily caused heart failure, and heart weakens because of disease, overwork, ejection function, so that row
Blood volume can not meet organ and anabolic needs；Patient with angina pectoris can occur the complication such as arrhythmia, shock, often can endanger
And life.
Owing to angina pectoris is one of situation the most high-risk in heart disease symptom, if can not get giving treatment in time has the most very much
May threat to life, emergency measures fast and effectively and send institute's treatment the most particularly important timely, but much patients
It is in what it was rescued or sent to hospital by remoter place, the distance hospital inconvenient rescue personnel such as farther out in time during morbidity
Situation, then be accomplished by patient and save oneself, by sucking or inject the medicine of certain relief of symptoms, strives for rescue time,
Thus reduce the situation that severe complication is even dead.
The chemical formula of nitroglycerin is 1,2,3-glycerol trisnitrate:
。
Nitroglycerin, as the common drug for the treatment of heart disease, is to treat one of first-selected medicine of angina pectoris.Its mechanism
Mainly by load before and after expansion peripheral blood vessel reduction heart, expansion coronary arteries reduces myocardial oxygen consumption and plays a role, and reaches
Antianginal effect.Additionally, nitroglycerin also can make peripheral vascular resistance decline by expanding other tremulous pulsies, vein, thus
Alleviate the burden of heart, increase heart blood discharge amount, improve the mechanisms play Antianginal effects such as heart and blood circulation.
At present, domestic listing nitroglycerin mainly has tablet, injection, aerosol, and nitroglycerin tablet can not be swallowed,
This is because the nitroglycerin swallowed must pass through liver in absorption process, in liver, the nitroglycerin of the overwhelming majority is gone out
Living, so that drug effect is substantially reduced, bioavailability is only 8%, and during sublingual administration, the blood capillary that medicine is enriched by oral cavity
Pipe is directly absorbed into blood circulation rapidly, and bioavailability may be up to 80%.Owing to buccal tablets is short for action time, Sublingual contains
Change only 1～4 minute half-life, be used for preventing angina pectoris attacks improper.Injection is rapid-action, but uses restricted, limitation ratio
Relatively big, it is limited to the most to the greatest extent hospital's curing patient, patient can not oneself use.Aerosol need pressure vessel, valve system and
Special production equipment, relatively costly；Aerosol has certain pressure, heat and after being impacted it may happen that blast and due to
Containing propellant, there is certain toxicity, therefore be not suitable for cardiac and use as inhalation aerosol.
Summary of the invention
Therefore present invention mainly solves prior art problem, exploitation one treats angina pectoris Neulized inhalation preparation, and self
The aerosol of the aerosolizable suction without propellant formed, has that atomizing effect is good, absorb fast, rapid-action feature.
For achieving the above object, the present invention adopts the following technical scheme that
A kind of being used for treats an anginal Neulized inhalation preparation, medicinal liquid be placed in atomising device and obtain, described medicinal liquid bag
Include active constituents of medicine nitroglycerin, solvent and pharmaceutically acceptable carrier, wherein the concentration of nitroglycerin be 0.1～
10mg/ml, described solvent can be water and or alcohol mixture, described pharmaceutically acceptable carrier includes stabilizer, isotonic
Agent, PH regulator.
Described stabilizer be in propylene glycol, ethanol and glycerol one or more mixing, the concentration of stabilizer be 0.1～
10mg/ml。
Described isotonic agent is one or more mixing in sodium chloride, potassium chloride, glucose, mannitol, and isotonic agent is dense
Degree is 5～9mg/ml.
Described PH regulator is one or more in citric acid, sodium citrate, lactic acid, sodium lactate, hydrochloric acid, sodium hydroxide
Mixing, pH value is adjusted to 3.5～5.5.
Described atomising device can be hand-held nebulizer, air compression type nebulizer, oxygen atomizer, metered dose atomization
Device.
By the enforcement of above technical scheme, the present invention compared with prior art concrete advantages below:
The used administering mode of the present invention is simple to operation, it is easy to patient accepts.When client need is saved oneself, medicinal liquid is put
Inhalation in atomising device, can fast and effeciently relief of symptoms, rescue for patient or send institute's treatment to provide sufficiently long
Slack time, thus improve the survival probability after angina pectoris morbidity.And, the present invention treats angina pectoris Neulized inhalation system
Agent in use, after medicinal liquid is sprayed by atomising device, forms the little molecule of medicinal liquid, then by the mucosa absorption of mouth and nose, has
Absorb fast, rapid-action feature, win the more time for patient's first aid, improve the survival after angina pectoris morbidity several
Rate.
Detailed description of the invention:
Now the present invention is described in more detail by following example of formulations, but limits the present invention never in any form.
Embodiment 1:
| Nitroglycerin | 0.5g |
| Propylene glycol | 10.0g |
| Glucose | 4.5g |
| Citric acid | 0.1g |
| Pure water adds to | 100ml |
Technique: weigh nitroglycerin, propylene glycol, glucose, citric acid add in pure water heated and stirred to after being completely dissolved, pure
Water purification is settled to full dose, is filtered by sterilizing filter by gained solution, then by liquid medicine filling in 2～5ml ampoule bottles, i.e.
Obtain nitroglycerin Neulized inhalation preparation.
Embodiment 2:
| Nitroglycerin | 1.0g |
| Ethanol | 10.0g |
| Sodium chloride | 7.5g |
| Lactic acid | 0.1g |
| Pure water adds to | 100ml |
Technique: weigh nitroglycerin, ethanol, sodium chloride, lactic acid add in pure water heated and stirred to after being completely dissolved, pure water
It is settled to full dose, gained solution is filtered by sterilizing filter, then liquid medicine filling is pacified in 2～5ml Low Density Polyethylenes
In small jar bottle, obtain nitroglycerin Neulized inhalation preparation.
Embodiment 3:
| Nitroglycerin | 0.1g |
| Ethanol | 7.0g |
| Propylene glycol | 20.0g |
| Glucose | 4.5g |
| Citric acid | 0.1g |
| Pure water adds to | 100ml |
Technique: weigh nitroglycerin, propylene glycol, ethanol, glucose, citric acid add in pure water heated and stirred to being completely dissolved
After, pure water is settled to full dose, is filtered by sterilizing filter by gained solution, then by liquid medicine filling in 2～5ml low-density
In polyethylene ampoule bottle, obtain nitroglycerin Neulized inhalation preparation.
Claims (6)
1. for the anginal Neulized inhalation preparation for the treatment of, medicinal liquid it is placed in atomising device and obtains, it is characterised in that
Described medicinal liquid includes active constituents of medicine nitroglycerin, solvent and pharmaceutically acceptable carrier, wherein nitroglycerin
Concentration is 0.1～10mg/ml, described solvent can be water and or alcohol mixture, described pharmaceutically acceptable carrier includes
Stabilizer, isotonic agent, PH regulator.
The most according to claim 1 for treating anginal Neulized inhalation preparation, it is characterised in that described stabilizer
For one or more mixing in propylene glycol, ethanol and glycerol, the concentration of stabilizer is 0.1～10mg/ml.
The most according to claim 1 for treating anginal Neulized inhalation preparation, it is characterised in that described isotonic agent
For one or more mixing in sodium chloride, potassium chloride, glucose, mannitol, isotonic agent concentration is 5～9mg/ml.
The most according to claim 1 for treating anginal Neulized inhalation preparation, it is characterised in that described PH regulator
For in citric acid, sodium citrate, lactic acid, sodium lactate, hydrochloric acid, sodium hydroxide one or more mixing, pH value be adjusted to 3.5～
5.5。
The most according to claim 1 for treating anginal Neulized inhalation preparation, it is characterised in that described atomising device
Can be hand-held nebulizer, air compression type nebulizer, oxygen atomizer, metered dose nebulizer.
The most according to claim 1 for treating anginal Neulized inhalation preparation, it is characterised in that described in preparation 100ml
Medicinal liquid use following prescription: nitroglycerin 0.5g, propylene glycol 10.0g, glucose 4.5g, citric acid 0.1g, add with pure water
To 100ml；And use following preparation method to prepare: weigh nitroglycerin, propylene glycol, glucose, citric acid add pure
In water, heated and stirred is to after being completely dissolved, and pure water is settled to full dose, is filtered by sterilizing filter by gained solution, then will
Liquid medicine filling, in 2～5ml ampoule bottles, obtains nitroglycerin Neulized inhalation preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610772974.0A CN106176693A (en) | 2016-08-31 | 2016-08-31 | One is used for treating angina pectoris Neulized inhalation preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610772974.0A CN106176693A (en) | 2016-08-31 | 2016-08-31 | One is used for treating angina pectoris Neulized inhalation preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176693A true CN106176693A (en) | 2016-12-07 |
Family
ID=58089040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610772974.0A Pending CN106176693A (en) | 2016-08-31 | 2016-08-31 | One is used for treating angina pectoris Neulized inhalation preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176693A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021227540A1 (en) * | 2020-05-10 | 2021-11-18 | 王安 | Healthcare device for tonifying vitality of human body |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389609A (en) * | 2011-06-29 | 2012-03-28 | 田中枢 | Portable heart disease first aid administration device |
| CN202289115U (en) * | 2011-10-29 | 2012-07-04 | 王志萍 | Nitroglycerin nasal spraying device |
| CN102924302A (en) * | 2012-11-07 | 2013-02-13 | 陕西合成药业有限公司 | Injection-grade ambroxol hydrochloride and solution for inhalation of injection-grade ambroxol hydrochloride |
-
2016
- 2016-08-31 CN CN201610772974.0A patent/CN106176693A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389609A (en) * | 2011-06-29 | 2012-03-28 | 田中枢 | Portable heart disease first aid administration device |
| CN202289115U (en) * | 2011-10-29 | 2012-07-04 | 王志萍 | Nitroglycerin nasal spraying device |
| CN102924302A (en) * | 2012-11-07 | 2013-02-13 | 陕西合成药业有限公司 | Injection-grade ambroxol hydrochloride and solution for inhalation of injection-grade ambroxol hydrochloride |
Non-Patent Citations (1)
| Title |
|---|
| 南京药学院: "《药剂学》", 31 March 2016 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021227540A1 (en) * | 2020-05-10 | 2021-11-18 | 王安 | Healthcare device for tonifying vitality of human body |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011200464B2 (en) | Inhalable formulations for treating pulmonary hypertension and methods of using same | |
| CN101287457B (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| CN1187044C (en) | Storable active substance concentrate with formoterol | |
| JP2021503468A5 (en) | ||
| WO2010126818A1 (en) | Intranasal delivery system for dantrolene | |
| CN103462942B (en) | A kind of suction ambroxol hydrochloride solution | |
| CN106176693A (en) | One is used for treating angina pectoris Neulized inhalation preparation | |
| WO2022199049A1 (en) | Use of ulinastatin in preparation of drug for treating novel coronavirus pneumonia | |
| AU2014356392A1 (en) | Sprayable aqueous composition comprising glyceryl trinitrate | |
| CN106667974A (en) | Preparation method of terbutaline sulfate solution for inhalation | |
| CN1969814B (en) | Nasal administered preparation of melatonin | |
| CN106265624A (en) | The treatment pharmaceutical composition of breast carcinoma, drug delivery system and preparation method thereof | |
| CN102440957B (en) | Terlipressin acetate nasal cavity spray and preparation method thereof | |
| JP5435659B2 (en) | Formulation form for oral mucosal administration of triptan | |
| JP2010248263A (en) | A therapeutic agent for tachyarrhythmia containing landiolol hydrochloride | |
| WO2010094218A1 (en) | Oral spray or aerosol of palonosetron | |
| CN100415226C (en) | An electrolyte supplement for treating hypokalemia and hypomagnesemia and its application | |
| EP3256216B1 (en) | Milrinone composition and method for administering same | |
| CN102525891A (en) | Adenosine cyclophosphate injection and preparation method thereof | |
| WO2024210922A1 (en) | Compositions for antihypertensive drugs | |
| CN102871968B (en) | Preparation of sildenafil rhubarb hydrochloric acid salt medicine granules and preparation of suction type aerosol of gradules | |
| CN114306220A (en) | Inhalation preparation, preparation method and application thereof | |
| CN1689565A (en) | Rimantadine compound anti-cold preparation | |
| BG1841U1 (en) | Parenteral dosage form | |
| CN107648226A (en) | A kind of pharmaceutical composition for treating antimigraine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |